Mesalamine Therapy

The most widespread chronic inflammatory disorder after rheumatoid arthritis is the inflammatory bowel disease (IBD). Millions of people suffer from Crohn's disease, which is also an IBD. In addition, the number of people is constantly increasing. The cause of the disease is not yet known. It is the terminal ileum and colon that are usually affected by this disease but it can affect any other part of the digestive tract too.

Currently there are effective treatments for Crohn's disease, but they are few. In addition, none of these treatments can trust as a maintenance therapy successfully. Therefore, research has been conducted to gain new information for Crohn's disease. Prednisone and prednisolone were once considered an effective treatment, but according to new information, they are only good for induction of remission. Understanding this, they have negative affects different. Bearing in mind the high toxicity of these drugs, they have been kept reserved for patients with moderate to severe disease.

New information for Crohn's disease includes the introduction of budesonile. It was considered a significant advance in this field. Although oral form, it is as effective as prednisolone in inducing remission in those who suffer from Crohn's disease and at the same time, it leads to relatively less adrenal suppression and have fewer side effects. It was observed that the slow-release formulation of budesonide is higher when compared to the formulation of mesalamine to treat Crohn's disease. However, according to new information for Crohn's disease on budesonide, the next step should be to determine which patients with the disease can have a maximum benefit of therapy budenoside.

One thing to consider is the successor budenoside conventional glucocorticoids, which are used to take several years to treat Crohn's disease. On the other hand, mesalamine is a newer version of sulfasalazine.

Although the search for new information for Crohn's disease, it is noted that there has been remarkable progress in this area, which include changes to known treatments. For example, today patients refractory or-dependent glucocotricoid can take methotrexate. In addition, patients through the suffering of Crohn's disease can now have a place to ciprofloxacin or mercaptopurine. Other than these drugs, there are now new treatments such as immunomodulators, which are specially prepared to intervene with primary pathogenic mechanisms of intestinal inflammation.

To summarize, we can say that if research into the causes and cure for Crohn's disease continues, these treatments provide patients an effective maintenance therapy.